← Gilead Sciences overview

Gilead Sciences vs Euro/US Dollar FX Spot Rate: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Gilead Sciences Inc (GILD)

Q3 2026
▲3▼1

Gilead Q3: HIV strength, new launches, but big writedown weighs

  • Q2 revenue up 10%, HIV sales up 12%, guidance raised Gilead's second-quarter revenue rose 10% to $7.8 billion, with HIV sales up 12%, and the company raised its full-year guidance. This shows the core business is growing and management is more confident about the future.

    This is the main positive force behind the stock this quarter, showing stronger sales and a brighter outlook.

  • Four planned launches and new approvals broaden business beyond HIV Gilead is preparing four new product launches and won approvals for Bixlenvo and a Trodelvy/Keytruda combination. This diversification reduces reliance on HIV and opens new revenue streams, which supports the stock.

    It shows concrete progress in expanding beyond HIV, a key part of the bull case this quarter.

  • Legal win protects Biktarvy; PAHO deal expands lenacapavir access Gilead won a legal case protecting its key HIV drug Biktarvy from generic competition, and signed a deal with PAHO to expand access to lenacapavir. These reduce competitive threats and open new markets, helping the stock.

    These events remove a major risk and add a growth avenue, both new this quarter.

  • $11.2B acquired IPR&D charge causes $8.45 GAAP loss Gilead reported a GAAP loss of $8.45 per share due to an $11.2 billion charge for acquired in-process research and development. This accounting charge weighed on reported earnings, though it doesn't reflect cash flow or ongoing operations.

    It is the main negative factor this quarter, explaining why reported earnings looked bad despite strong sales.

September 2026
▲4

Gilead's HIV franchise strengthens with legal win, access deal, and analyst backing

  • Fourth Circuit blocks illegal imports of Biktarvy A federal appeals court upheld an injunction stopping foreign versions of Gilead's top HIV drug Biktarvy from being sold in the U.S. This protects Gilead's U.S. sales and pricing power, supporting the stock.

    This legal win directly protects Gilead's largest revenue stream and removes a competitive threat.

  • PAHO deal expands lenacapavir access in Latin America Gilead and the Pan American Health Organization agreed to make HIV prevention drug lenacapavir available in 14 Latin American countries. This widens the market for Gilead's prevention portfolio, though pricing terms are still unclear.

    This expands Gilead's global reach for a key growth drug, but the financial impact depends on final pricing.

  • Morgan Stanley reaffirms Overweight on HIV prevention growth Morgan Stanley kept its buy rating on Gilead, highlighting the HIV prevention franchise. Yeztugo, a twice-yearly shot, is expected to hit $1 billion in first-year sales, with the prevention portfolio at about $4 billion annually and PrEP users more than doubling since 2022.

    Analyst backing and concrete sales targets reinforce confidence in Gilead's growth trajectory.

  • Gilead's pipeline advances with gamgertamig and anito-cel Lakefront Biotherapeutics plans registrational trials in 2027 for gamgertamig, which Gilead will commercialize. Also, Gilead's anito-cel for multiple myeloma has an FDA decision due in December. These add future growth options beyond HIV.

    Pipeline progress diversifies Gilead's revenue and offers new catalysts, though they are not yet near-term revenue.

Latest
▲4

Gilead's HIV franchise strengthens with legal win, access deal, and analyst backing

  • Fourth Circuit blocks illegal imports of Biktarvy A federal appeals court upheld an injunction stopping foreign versions of Gilead's top HIV drug Biktarvy from being sold in the U.S. This protects Gilead's U.S. sales and pricing power, supporting the stock.

    This legal win directly protects Gilead's largest revenue stream and removes a competitive threat.

  • PAHO deal expands lenacapavir access in Latin America Gilead and the Pan American Health Organization agreed to make HIV prevention drug lenacapavir available in 14 Latin American countries. This widens the market for Gilead's prevention portfolio, though pricing terms are still unclear.

    This expands Gilead's global reach for a key growth drug, but the financial impact depends on final pricing.

  • Morgan Stanley reaffirms Overweight on HIV prevention growth Morgan Stanley kept its buy rating on Gilead, highlighting the HIV prevention franchise. Yeztugo, a twice-yearly shot, is expected to hit $1 billion in first-year sales, with the prevention portfolio at about $4 billion annually and PrEP users more than doubling since 2022.

    Analyst backing and concrete sales targets reinforce confidence in Gilead's growth trajectory.

  • Gilead's pipeline advances with gamgertamig and anito-cel Lakefront Biotherapeutics plans registrational trials in 2027 for gamgertamig, which Gilead will commercialize. Also, Gilead's anito-cel for multiple myeloma has an FDA decision due in December. These add future growth options beyond HIV.

    Pipeline progress diversifies Gilead's revenue and offers new catalysts, though they are not yet near-term revenue.

August 2026
▲3▼1

Gilead Q2 beat, HIV strength, new drug approvals, but accounting loss

  • Q2 earnings beat and raised guidance Gilead's second-quarter revenue rose 10% to $7.8 billion, with HIV sales up 12% and PrEP topping $1 billion. The company raised its full-year HIV growth outlook to 9–10%, signaling confidence.

    This is the main positive force behind the stock, showing strong operational performance.

  • New HIV and cancer drug approvals The FDA approved Bixlenvo, a new single-tablet HIV regimen, and the EU expanded Trodelvy plus Keytruda for first-line triple-negative breast cancer. These expand Gilead's product lineup and market reach.

    These approvals are new revenue drivers and reinforce Gilead's competitive position.

  • Large accounting loss from acquisitions Gilead reported a GAAP loss of $8.45 per share due to $11.2 billion in acquired IPR&D charges from Arcellx, Tubulis, and Ouro Medicines. This is an accounting charge, not an operational loss, but it weighed on reported earnings.

    This explains the headline loss and why it may not reflect underlying business health.

  • Analyst confidence and pipeline progress BofA reiterated a Buy rating with a $162 target, and Gilead advanced its pipeline in oncology and a once-weekly oral HIV regimen. However, these pipeline gains are early and not yet near-term revenue.

    Analyst support and pipeline advances support the stock, though with limited immediate impact.

▲4

Gilead's HIV engine accelerates with new drug approvals and raised guidance

  • HIV sales growth guidance raised to 9–10% Gilead lifted its full-year HIV sales growth outlook to 9–10% from 8%, citing a $4 billion annualized PrEP business and strong Biktarvy. Higher expected sales mean more profit, which supports a higher stock price.

    This is a direct, new upgrade to the company's core revenue outlook, a key driver of the stock.

  • FDA approves Bixlenvo, a new single-tablet HIV regimen The FDA approved Bixlenvo, a once-daily single tablet for complex HIV cases. It is the smallest such option and the first for patients who cannot take existing single-tablet therapies, opening a new market and reinforcing Gilead's HIV leadership.

    A new product approval expands the addressable market and future revenue, directly lifting growth prospects.

  • European Commission expands Trodelvy approval in first-line TNBC The EC approved Trodelvy plus Keytruda for first-line metastatic triple-negative breast cancer, making it the only antibody-drug conjugate plus immunotherapy combo in that setting across the EU. This widens oncology sales and diversifies revenue beyond HIV.

    A major regulatory win in a new indication that boosts the oncology franchise and long-term growth.

  • Pipeline expands with MacroGenics option and once-weekly HIV data Gilead exercised an option on a MacroGenics bispecific cancer program, and positive Phase 3 results for a once-weekly oral HIV regimen with Merck were announced. These add future growth options, though they are early and not yet near-term revenue.

    New pipeline additions signal longer-term growth potential, which can support a higher valuation.

▲3▼1

Gilead's Q2 beat and raised guidance show HIV strength, but acquisition charges hit reported EPS

  • Q2 revenue beat and raised full-year guidance Gilead reported Q2 revenue of $7.8 billion, up 10% and above estimates, and raised 2026 product sales guidance to $29.8–$30.1 billion. HIV sales rose 12% to $5.7 billion, with Biktarvy up 7%. This shows the core business is growing faster than expected, which supports a higher stock price.

    This is the period's central event and directly explains the positive fundamental momentum behind GILD.

  • PrEP franchise tops $1 billion; Yeztugo persistence strong Quarterly PrEP sales doubled year-over-year to over $1 billion for the first time, led by the twice-yearly shot Yeztugo ($232 million, up 40% from Q1). Over 70% of patients stayed on Yeztugo after a year, the best among PrEP options. This growing prevention business adds a new revenue stream and reduces reliance on HIV treatment alone.

    It highlights a key new growth driver that is boosting investor confidence and future sales.

  • Large acquisition charges push reported EPS deeply negative Gilead's Q2 GAAP EPS was a loss of $8.45, and non-GAAP EPS was a loss of $6.75, due to $11.2 billion in acquired IPR&D expenses from buying Arcellx, Tubulis, and Ouro Medicines. Excluding these one-time charges, EPS would be $8.50–$8.85. The headline loss may scare some investors, but it is an accounting effect, not a cash drain on operations.

    It is the main counterweight in the period and explains why reported earnings look bad despite strong operations.

  • Analyst reiterates Buy; pipeline advances in oncology and HIV BofA reiterated a Buy rating and $162 price target, citing Yeztugo's persistence and raised guidance. Separately, European regulators backed Trodelvy plus Keytruda for first-line triple-negative breast cancer, and a once-weekly oral HIV regimen with Merck met its Phase 3 goals. These expand future sales opportunities.

    It shows external validation and pipeline progress that support the stock's longer-term growth story.

July 2026
▲4

Gilead's pipeline expands with new launches and positive HIV data

  • Four drug launches planned to diversify beyond HIV Gilead is preparing four drug launches this year, including bulevirtide for hepatitis delta and anito-cel for multiple myeloma. This diversification reduces reliance on HIV and opens new revenue streams, supporting the stock.

    This is a new strategic update that shows Gilead's growth beyond its core HIV business.

  • Positive Phase 3 results for once-weekly oral HIV regimen Gilead and Merck reported that a once-weekly oral HIV treatment maintained viral suppression in Phase 3 trials, with higher patient satisfaction. This could become the first once-weekly oral option, strengthening Gilead's HIV portfolio.

    This is a new clinical milestone that could lead to a new product and boost future sales.

  • CHMP recommends Trodelvy plus Keytruda for first-line TNBC The European regulator recommended Trodelvy combined with Keytruda for first-line metastatic triple-negative breast cancer. This expands Trodelvy's use and reinforces its role, potentially increasing sales in Europe.

    This is a new regulatory step that could lead to approval and broader use of a key drug.

  • Remdesivir evaluated in Ebola trial The WHO began an experimental Ebola trial in Congo, testing Gilead's remdesivir. If effective, it could expand remdesivir's use and demand, though the impact is uncertain and likely small.

    This is a new potential use for an existing drug, but the financial impact is not yet clear.

▲4

Gilead's pipeline expands with new launches and positive HIV data

  • Four drug launches planned to diversify beyond HIV Gilead is preparing four drug launches this year, including bulevirtide for hepatitis delta and anito-cel for multiple myeloma. This diversification reduces reliance on HIV and opens new revenue streams, supporting the stock.

    This is a new strategic update that shows Gilead's growth beyond its core HIV business.

  • Positive Phase 3 results for once-weekly oral HIV regimen Gilead and Merck reported that a once-weekly oral HIV treatment maintained viral suppression in Phase 3 trials, with higher patient satisfaction. This could become the first once-weekly oral option, strengthening Gilead's HIV portfolio.

    This is a new clinical milestone that could lead to a new product and boost future sales.

  • CHMP recommends Trodelvy plus Keytruda for first-line TNBC The European regulator recommended Trodelvy combined with Keytruda for first-line metastatic triple-negative breast cancer. This expands Trodelvy's use and reinforces its role, potentially increasing sales in Europe.

    This is a new regulatory step that could lead to approval and broader use of a key drug.

  • Remdesivir evaluated in Ebola trial The WHO began an experimental Ebola trial in Congo, testing Gilead's remdesivir. If effective, it could expand remdesivir's use and demand, though the impact is uncertain and likely small.

    This is a new potential use for an existing drug, but the financial impact is not yet clear.

Q2 2026
▲3▼1

Gilead's Trodelvy and HIV pipeline win key approvals, but earnings guidance weighs

  • FDA and EU approve Trodelvy for first-line triple-negative breast cancer Gilead won U.S. and European approval to use Trodelvy as an initial treatment for metastatic triple-negative breast cancer, a hard-to-treat disease. This opens a much larger patient group and could significantly boost sales, pushing the stock up.

    This is a major new approval that expands the market for a key drug, directly lifting future revenue prospects.

  • FDA accepts filing for once-weekly oral HIV prevention pill The FDA agreed to review Gilead's once-weekly oral PrEP, with a decision expected by February 2027. If approved, it would offer a more convenient option than the current twice-yearly injection, potentially growing the HIV prevention market and lifting GILD.

    This regulatory milestone advances a new HIV prevention product, expanding Gilead's HIV franchise.

  • Positive Phase 3 data for once-weekly oral HIV treatment with Merck Gilead and Merck reported positive late-stage results for a once-weekly oral HIV treatment combining islatravir and lenacapavir. This could simplify HIV therapy and strengthen Gilead's HIV portfolio, supporting the stock.

    New clinical success in HIV treatment adds a potential future revenue stream and reinforces Gilead's leadership.

  • Full-year EPS guidance misses despite revenue beat Gilead's Q1 revenue beat expectations, but its full-year earnings-per-share guidance missed significantly. This suggests cost pressures or lower profitability ahead, which can weigh on the stock even as sales grow.

    This is a new negative financial disclosure that could cap upside from the positive pipeline news.

June 2026
▲3▼1

Gilead's Trodelvy and HIV pipeline win key approvals, but earnings guidance weighs

  • FDA and EU approve Trodelvy for first-line triple-negative breast cancer Gilead won U.S. and European approval to use Trodelvy as an initial treatment for metastatic triple-negative breast cancer, a hard-to-treat disease. This opens a much larger patient group and could significantly boost sales, pushing the stock up.

    This is a major new approval that expands the market for a key drug, directly lifting future revenue prospects.

  • FDA accepts filing for once-weekly oral HIV prevention pill The FDA agreed to review Gilead's once-weekly oral PrEP, with a decision expected by February 2027. If approved, it would offer a more convenient option than the current twice-yearly injection, potentially growing the HIV prevention market and lifting GILD.

    This regulatory milestone advances a new HIV prevention product, expanding Gilead's HIV franchise.

  • Positive Phase 3 data for once-weekly oral HIV treatment with Merck Gilead and Merck reported positive late-stage results for a once-weekly oral HIV treatment combining islatravir and lenacapavir. This could simplify HIV therapy and strengthen Gilead's HIV portfolio, supporting the stock.

    New clinical success in HIV treatment adds a potential future revenue stream and reinforces Gilead's leadership.

  • Full-year EPS guidance misses despite revenue beat Gilead's Q1 revenue beat expectations, but its full-year earnings-per-share guidance missed significantly. This suggests cost pressures or lower profitability ahead, which can weigh on the stock even as sales grow.

    This is a new negative financial disclosure that could cap upside from the positive pipeline news.

▲3▼1

Gilead's Trodelvy and HIV pipeline win key approvals, but earnings guidance weighs

  • FDA and EU approve Trodelvy for first-line triple-negative breast cancer Gilead won U.S. and European approval to use Trodelvy as an initial treatment for metastatic triple-negative breast cancer, a hard-to-treat disease. This opens a much larger patient group and could significantly boost sales, pushing the stock up.

    This is a major new approval that expands the market for a key drug, directly lifting future revenue prospects.

  • FDA accepts filing for once-weekly oral HIV prevention pill The FDA agreed to review Gilead's once-weekly oral PrEP, with a decision expected by February 2027. If approved, it would offer a more convenient option than the current twice-yearly injection, potentially growing the HIV prevention market and lifting GILD.

    This regulatory milestone advances a new HIV prevention product, expanding Gilead's HIV franchise.

  • Positive Phase 3 data for once-weekly oral HIV treatment with Merck Gilead and Merck reported positive late-stage results for a once-weekly oral HIV treatment combining islatravir and lenacapavir. This could simplify HIV therapy and strengthen Gilead's HIV portfolio, supporting the stock.

    New clinical success in HIV treatment adds a potential future revenue stream and reinforces Gilead's leadership.

  • Full-year EPS guidance misses despite revenue beat Gilead's Q1 revenue beat expectations, but its full-year earnings-per-share guidance missed significantly. This suggests cost pressures or lower profitability ahead, which can weigh on the stock even as sales grow.

    This is a new negative financial disclosure that could cap upside from the positive pipeline news.

Euro/US Dollar FX Spot Rate (EURUSD.FOREX)

Latest
▼3▲1

Euro hits 17-month low as French debt fears and Fed rate bets boost dollar

  • French debt crisis and political gridlock sink euro Investors are dumping French bonds and stocks as public debt heads toward 120% of GDP, pushing the French-German bond spread to 141 basis points. This political and fiscal risk makes the euro less attractive, pushing EURUSD down to its lowest since May 2025.

    This is the main new force driving the euro lower this period.

  • US bond yields surge, Fed rate hike bets rise US 10-year Treasury yields jumped above 5.2%, the highest since 2002, as oil prices climbed and Fed officials backed further rate hikes. Higher US rates make dollar deposits more attractive, strengthening the dollar and pushing EURUSD down.

    This is a key new driver of dollar strength this period.

  • Eurozone inflation beats forecasts, keeping ECB hike pressure alive Eurozone September inflation rose to 3.8%, above the 3.6% forecast, with core inflation up to 2.5%. This keeps pressure on the ECB to raise rates further, which supports the euro by attracting global money into euro deposits.

    This is a new counterweight that could support the euro despite the negative drivers.

  • Energy shock and political risk weigh on euro outlook European gas prices above €80/MWh and the war in Iran disrupting LNG shipments are hurting Europe's economy. Meanwhile, far-right gains in Germany and France's political gridlock add uncertainty. These factors make the euro less attractive, pushing EURUSD down.

    This explains the broader negative backdrop for the euro this period.

Q3 2026
▲2▼1

Euro swings from two-month high to 17-month low as Fed hikes and French debt fears dominate

  • Euro hits two-month high on weak US jobs and split Fed The euro climbed to a two-month high near 1.166 as weak US jobs data and a divided Federal Reserve weakened the dollar, while solid eurozone activity and expected ECB rate hikes supported the currency.

    This explains the euro's peak during the period, driven by US dollar weakness and eurozone strength.

  • Euro plunges to 17-month low on Fed hikes and French debt The euro fell to a 17-month low as Federal Reserve rate hikes, 5.2% Treasury yields, French debt concerns, German far-right election gains, and energy shocks weighed heavily on the currency.

    This captures the main downward driver that pushed the euro to its lowest level in 17 months.

  • ECB rate hikes to 2.50% and resilient PMI offer partial support The European Central Bank raised rates to 2.50% and eurozone business activity remained resilient, providing only partial support to the euro amid broader negative forces.

    This shows the counterweight that limited the euro's decline, balancing the negative drivers.

September 2026
▼3▲1

Euro Falls to 17-Month Low as Dollar Strength and Eurozone Risks Dominate

  • Dollar Strength on Fed Hikes and High Yields The Fed raised rates to 3.75–4.00% and US 10-year yields topped 5.2%, pulling global money into dollar assets. This made the dollar more attractive and pushed the euro down.

    This is a key new force that drove EURUSD lower during the period.

  • Eurozone Political and Fiscal Risks Weigh on Euro France's debt neared 120% of GDP with widening bond spreads, and far-right gains in German elections raised concerns. These risks made investors wary of holding euros.

    New political developments added downward pressure on the euro.

  • Energy Shocks Hurt Europe's Growth Outlook Brent crude rose above $100 and natural gas above €80/MWh, raising costs for European businesses and consumers. This weakened the eurozone economy and weighed on the euro.

    Energy price spikes are a new negative factor for the euro.

  • ECB Hikes and Resilient Economy Support Euro Eurozone inflation hit 3.8%, prompting the ECB to raise rates to 2.50% and signal more tightening. The economy held up with PMI at 53.1, attracting some foreign capital.

    This positive force partially offset the euro's decline and is new this period.

▲2▼2

Eurozone data and ECB signals support euro, but US yields and politics weigh

  • Eurozone economy unexpectedly strong, supports euro The eurozone's business activity index jumped to 53.1 in September, the highest in over three years, beating expectations. A stronger economy makes the euro more attractive and supports further ECB rate hikes, pushing EURUSD up.

    This is new data showing eurozone resilience, which strengthens the euro.

  • ECB officials hint at more rate hikes to fight inflation ECB's Nagel said rates may need to become restrictive, and Makhlouf said the ECB would act if energy prices spill over. BofA expects a December hike. Higher expected euro rates attract global money, pushing EURUSD up.

    New hawkish comments from ECB officials and BofA's forecast reinforce expectations of higher euro rates.

  • US bond yields surge and Fed officials back more hikes The 10-year US Treasury yield rose above 5%, the highest in 19 years, after strong US business activity data. Fed's Collins, Musalem, and Barr supported further rate hikes. Higher US rates make the dollar more attractive, pushing EURUSD down.

    New US data and Fed comments drive dollar strength, a key counterweight to the euro.

  • German political risk and ECB's Lane downplays wage pressure Germany's far-right party won a major regional election, weakening the coalition and raising political uncertainty. ECB's Lane said no strong wage pressure, suggesting fewer hikes. These factors weigh on the euro, pushing EURUSD down.

    New political and monetary developments that could undermine euro strength.

▲1▼1

ECB hikes and signals more, but Fed's first hike in three years lifts dollar

  • Markets price more ECB hikes; banks see 2.75% or higher Money markets now price more than four additional ECB hikes, and banks like Barclays, Goldman and Rabobank expect another 25bp move in December to 2.75%. Expectations of higher-for-longer euro rates attract foreign capital into the euro, supporting EURUSD.

    Shows how far investors expect euro rates to rise, a key support for the euro.

  • Fed hikes to 3.75-4.00%, first rise in three years The Fed raised rates on September 16, six days after the ECB, and strong US retail sales and 3.4% inflation backed the move. Higher US rates make dollar deposits more attractive, strengthening the dollar and pushing EURUSD down to about 1.1450.

    The Fed's hike is the main new force pulling EURUSD down this period.

  • Oil and gas above ECB assumptions keep inflation high Brent above $100 and natural gas above €83/MWh exceed the ECB's worst-case assumptions, so inflation may stay high longer. This keeps the ECB tightening, which supports the euro, but high energy also hurts Europe's growth and can push investors to the dollar.

    Energy prices are the underlying force driving both ECB tightening and euro weakness.

▲3▼1

ECB hikes to 2.50% and signals more, lifting euro despite US rate pushback

  • ECB delivers first hike in two meetings, signals more The ECB raised its deposit rate to 2.50% on September 10, its second hike this year, and said inflation will stay above target through 2028. Higher euro interest rates attract global money into the euro, pushing EURUSD up. Markets now expect at least one more hike by year-end.

    The ECB's actual rate hike and further-hike signal is the main new force lifting the euro.

  • Eurozone economy resilient, ECB raises growth forecast ECB President Lagarde said she was surprised by the economy's resilience, with defense, infrastructure and AI investment supporting growth. The ECB raised its 2026 growth forecast to 0.9%. A stronger economy makes the euro more attractive and supports further rate hikes, pushing EURUSD up.

    Economic resilience gives the ECB room to keep rates high, reinforcing euro strength.

  • US rate-hike odds jump on hot PPI, capping euro US producer price inflation rose 5.4% in August, above expectations, and markets now price a 70% chance of a Fed hike on September 16, up from 61%. Higher expected US rates make dollar deposits more attractive, strengthening the dollar and limiting EURUSD's rise.

    This is the main counterweight: US rate expectations are rising too, which caps the euro's gains.

  • Oil above $100 fuels inflation, keeping ECB hawkish Brent crude surged past $105 as Middle East conflict cut energy exports, pushing eurozone inflation to 3.3%. The ECB hiked to prevent energy costs spreading. While high oil can hurt growth, it keeps the ECB tightening, which supports the euro against the dollar.

    Oil-driven inflation is the reason the ECB is hiking, directly linking energy prices to euro strength.

▲2▼1

ECB hike bets build on energy inflation; US intervention and Fed pushback cap euro

  • Eurozone inflation jumps, ECB hike bets build Eurozone inflation rose to 3.3% in August from 2.9%, driven by energy, and producer prices jumped 5.8%. Officials like Holzmann and Nagel pushed for more tightening, and markets now price a September ECB hike with near certainty. Higher expected euro interest rates pull global money into the euro, pushing EURUSD up.

    Rising euro-area inflation and hawkish ECB signals are the main new force lifting the euro.

  • Banks see ECB hiking further, rates staying higher JPMorgan and BNP Paribas now expect an extra ECB hike in December, and DBS sees the deposit rate at 2.50%, citing sticky inflation and resilient growth. Expectations of higher-for-longer euro rates attract foreign capital into the euro, supporting EURUSD.

    New forecasts of further ECB tightening extend the rate advantage that supports the euro.

  • US euro-selling intervention and Fed pushback weigh on euro European central bankers are frustrated that the US sold euros to buy yen without warning, and Bundesbank's Nagel called it a surprise. The extra euro supply weakens the euro. Meanwhile, Fed's Waller backed holding US rates, and strong August US jobs raised hike odds, both supporting the dollar and pushing EURUSD down.

    This is the main counterweight: US policy actions and data that strengthen the dollar against the euro.

  • ECB's blockchain euro plan could support long-term demand ECB's Schnabel pushed for issuing a blockchain-based euro, rejecting stablecoins, with the Pontes project launching next month. If it makes the euro more useful in digital finance, it could gradually raise demand for euros. But the effect is long-term and small for now, so it is a minor support.

    A new structural initiative that could affect future euro demand, though not an immediate price driver.

August 2026
▲2▼2

Euro Hits Two-Month High on Dollar Weakness, but Gains Capped

  • Dollar Weakness Lifts Euro Weak US jobs data and a split Fed cut September rate-hike odds, pushing the euro to a two-month high near 1.166. Treasury buybacks and Middle East de-escalation also weighed on the dollar.

    This is the main new driver of the euro's rise in August 2026.

  • Strong Eurozone Data and Hawkish ECB Support Euro Strong German trade and solid eurozone activity boosted the euro. The ECB stayed hawkish, with a September hike to 2.50% increasingly expected, making the euro more attractive.

    This is a new positive factor for the euro in August 2026.

  • US Intervention and Fed Comments Cap Euro US intervention selling euros to buy yen added euro supply and strained ECB cooperation. Fed Chair Warsh's Jackson Hole remarks and hot US PCE inflation revived US hike bets, strengthening the dollar.

    These new counterweights limited the euro's gains in August 2026.

  • Risks Tilt Against Euro Falling eurozone inflation expectations threatened ECB resolve, while stalled Iran talks and a possible US-Japan currency alliance kept risks tilted against the euro.

    These new risks prevented further euro strength in August 2026.

▼3▲1

ECB September hike bets build, but Fed pushback caps euro

  • ECB September rate hike increasingly expected The ECB is set to raise its policy rate to 2.50% in September to stop war-driven energy inflation spreading, and official Schnabel said more tightening is needed. Higher expected euro interest rates attract global money into the euro, pushing EURUSD up.

    A near-certain ECB hike is the main force lifting the euro this period.

  • Fed Chair Warsh hints at a US rate hike At Jackson Hole, Fed Chair Warsh said there is 'work to do' on inflation, lifting the chance of a September US hike to about 57.5% from 35%. Higher expected US rates make dollar deposits more attractive, strengthening the dollar and pushing EURUSD down.

    This is the main new counterweight that pulled the euro back from its highs.

  • Hot US inflation surprise supports the dollar A hotter-than-expected US PCE inflation reading on August 27 pushed US rates and the dollar up, sending EURUSD to about 1.1650. Stronger US inflation keeps the Fed from easing, which supports the dollar and weighs on the euro.

    It shows the US side of the rate story that is capping the euro.

  • US-Japan currency alliance keeps selling euros Citi says the US-Japan interventions reflect an informal currency alliance, with Washington selling euros to buy yen and possibly acting again if EUR/JPY nears 185-186. Extra euro supply in the market weakens the euro against the dollar.

    It is a real, ongoing drag on the euro that readers should not overlook.

▲3▼1

Euro hits two-month high as Fed hike bets fade and ECB stays hawkish

  • Fed rate-hike bets collapse, dollar loses its yield appeal US jobs data stayed weak and the Fed kept rates unchanged with a split committee, so traders cut the chance of a September hike to about 35% from 52% a week earlier. Lower expected US interest rates make dollar deposits less attractive, pushing EURUSD up.

    This is the main new force weakening the dollar and lifting the euro this period.

  • US Treasury buybacks and Middle East de-escalation weaken the dollar The US Treasury said it would more than double its bond buybacks to add market liquidity, which pushed the dollar down broadly and the euro up to about 1.166. Progress in Iran talks to reopen the Strait of Hormuz also cut safe-haven demand for the dollar.

    These are new events that directly weakened the dollar and pushed EURUSD to a two-month high.

  • Eurozone economy strengthens, keeping ECB hike on the table Eurozone business activity hit its highest since last November, with new orders growing fastest in 40 months and hiring rising for the first time this year. ECB official Lane said 3% inflation is too high. A stronger economy and likely ECB hike attract money into the euro.

    New eurozone data and ECB comments support the euro side of the pair.

  • Counterweight: consumers see lower inflation, and Middle East risk lingers Eurozone consumers' inflation expectations fell for a third month, which could soften the ECB's willingness to hike and cap the euro. Iran also threatened a fully offensive military posture after talks stalled, which could revive safe-haven dollar demand and push EURUSD down.

    This is the real counterweight that could stop the euro's rise, so readers get a fair picture.

July 2026
▲2▼2

Euro Rises on ECB Hawkishness and Weak US Data, but Gains Capped

  • ECB Hawkishness and Strong Eurozone Data Support Euro The European Central Bank kept a tough stance, with markets expecting more rate hikes as inflation stayed above target. Strong German and eurozone data, including GDP growth of 0.4% and high confidence, also lifted the euro.

    This explains a key force pushing the euro higher during the period.

  • Weak US Economic Data Weigh on Dollar Soft US inflation reports, weak GDP, and a Federal Reserve that held rates steady made the dollar less attractive. This helped push the euro to a six-week high near 1.1485.

    This highlights a major factor that weakened the dollar and supported the euro.

  • Oil Price Surge and Safe-Haven Demand Limit Euro Gains Oil prices above $100 due to Middle East tensions raised eurozone inflation but also hurt growth and increased bets on Fed rate hikes. This boosted dollar safe-haven demand, capping the euro's rise.

    This shows a counterweight that prevented larger euro gains.

  • Trade Tensions and Intervention Cap Euro Trump's tariff threats and a joint US-Japan intervention selling euros for yen added pressure. Eurozone inflation slowing to 2.8% in June also suggested the ECB might pause, limiting further euro strength.

    This points to other factors that restrained the euro's advance.

▲2▼1

ECB hike bets build as US data and yen intervention whipsaw the dollar

  • ECB signals September hike, lifting euro The ECB held its key rate at 2.25% but strongly hinted at a September hike, and markets now price the deposit rate near 2.7% by year-end and 3% by 2027. Higher expected euro interest rates attract global money into the euro, pushing EURUSD up.

    This is the main new force lifting the euro this period.

  • US-Japan joint intervention sells euros for yen The US and Japan jointly intervened to support the yen, selling euros to buy yen in a roughly $87 billion operation. This directly increased the supply of euros in the market, pushing the euro down against the dollar and adding geopolitical risk.

    This is a new, direct supply shock to the euro that weighs on EURUSD.

  • US data mixed: weak jobs, strong ISM and hawkish Fed Weak US jobs and soft data weakened the dollar, but strong ISM manufacturing and hawkish Fed comments later supported it. The tug-of-war between US rate-hike and rate-cut expectations keeps EURUSD volatile, with no clear direction from US data alone.

    US data is a key counterweight to the euro's rise, and its mixed nature explains the back-and-forth.

  • Eurozone GDP beats, supporting ECB hike case Eurozone second-quarter GDP rose 0.4%, beating forecasts, and business activity was strong. This supports the case for an ECB rate hike in September, making the euro more attractive to global investors and helping push EURUSD higher.

    Strong eurozone growth reinforces the ECB tightening story that lifts the euro.

▲2▼1

US jobs shock and euro-selling intervention drive euro to seven-week high

  • Weak US jobs report kills Fed rate-hike bets, lifting euro US July payrolls unexpectedly fell by 23,000, the first drop in five months, and wage growth slowed. Traders slashed the chance of a September Fed rate hike to about 44% from 58%. Lower expected US interest rates weaken the dollar, pushing EURUSD up to a seven-week high near 1.157.

    This is the main new force this period: a weak US economy makes the dollar less attractive, directly lifting the euro.

  • US sells euros to buy yen, weakening euro The US Treasury intervened to support the yen by selling euros and buying yen, without telling the ECB first. This directly increased the supply of euros in the market, pushing the euro down against the dollar. The ECB called it shocking, raising fears of strained central-bank cooperation.

    This is a new, direct action that weakens the euro and is a real counterweight to the euro's rally.

  • Strong German trade data supports euro German trade data came in better than expected, adding to signs that Europe's largest economy is holding up. A stronger eurozone economy makes the euro more attractive to global investors, helping push EURUSD higher alongside the weak US jobs news.

    It is a new eurozone-specific factor that supports the euro and helps explain the move to a seven-week high.

▲3▼1

Fed holds, US data weak, eurozone inflation up — euro hits six-week high

  • Fed holds rates, dollar falls broadly The Fed kept its key rate at 3.50–3.75% for a fifth straight meeting, with only three members wanting a hike. Because US rates are not rising, the dollar lost its appeal and fell, pushing EURUSD up to about 1.143.

    A steady Fed directly weakens the dollar, the main force lifting EURUSD this period.

  • Weak US GDP and cooling PCE knock dollar to six-week low US second-quarter GDP grew only 1.5%, below the 2.0% forecast, and core PCE inflation eased to 3.3%. Slower US growth and softer inflation mean the Fed is less likely to hike, weakening the dollar and lifting the euro to a six-week high.

    Soft US data reduce expected US rates, a key driver of dollar weakness and euro strength.

  • Eurozone GDP and confidence beat, inflation accelerates to 2.9% Eurozone second-quarter GDP rose 0.4% and economic confidence hit a five-month high, while July inflation accelerated to 2.9% on higher oil. Stronger growth and sticky inflation strengthen the case for ECB rate hikes, supporting the euro.

    Better eurozone data and higher inflation raise ECB hike odds, boosting the euro's rate appeal.

  • Trump tariff threat and oil spike weigh on euro Trump threatened steep tariffs on the EU after Brussels fined Google $1 billion, and Brent crude jumped over 6% on Iran tensions. Tariffs and costlier energy hurt the eurozone economy, a counterweight that could cap the euro's gains.

    This is the main risk pulling EURUSD down, balancing the positive drivers.

▲2▼1

Oil spike revives ECB hike bets, but dollar strength keeps euro pinned near 1.14

  • ECB signals possible September hike as oil-driven inflation risks rise The ECB held its key rate at 2.25% but President Lagarde strongly hinted at a September hike, calling inflation risks tilted to the upside. Higher expected euro interest rates attract global money into the euro, pushing EURUSD up.

    This is the main new monetary policy event of the period and directly supports the euro.

  • German 10-year bond yield hits 15-year high on ECB hike expectations Germany's 10-year yield surged to 3.21%, the highest since 2011, as markets priced two more ECB hikes by early 2027. Higher euro-area bond yields make euro deposits more attractive, lifting the euro against the dollar.

    Rising euro yields are a key channel through which ECB hike bets strengthen the euro.

  • Oil above $100 and Middle East attacks boost dollar safe-haven demand and Fed hike bets Houthi attacks on Saudi tankers sent Brent above $100, reigniting US inflation fears. Markets now price an 83% chance of a September Fed hike, up from 52% a week ago. Higher US rates and safe-haven flows strengthen the dollar, pushing EURUSD down.

    This is the main new force pulling EURUSD lower and is the counterweight to the ECB story.

  • SocGen warns oil spike may force ECB hikes but also sap eurozone growth Societe Generale says surging oil and gas could push the ECB to hike to 2.50% in September, but the same energy costs hurt eurozone growth. The bank sees a return above 1.1480 as a big ask, so the net effect on EURUSD is unclear.

    It fairly presents the real counterweight: higher energy prices can both help and hurt the euro.

▲2▼1

US inflation cools, Fed hike bets fade; euro rebounds but oil risks cap gains

  • Soft US CPI and PPI crush Fed rate-hike bets, lifting the euro US June consumer and producer inflation came in below forecasts, so traders slashed the chance of a Fed rate hike this month from 42% to 16% and for the year from 89% to 80%. Lower expected US rates weaken the dollar, pushing EURUSD up to a 3.5-week high near 1.1485.

    This is the main new force this period: softer US inflation directly reduces the dollar's rate advantage, a key driver of EURUSD.

  • Oil surge from Iran conflict cuts both ways for euro Renewed US-Iran fighting and sanctions sent oil up 9%, raising inflation fears. This could force the Fed to hike (dollar-positive) but also revives ECB hike bets (euro-positive). ING warns euro gains may stall above 1.1460 if oil keeps rising, as costlier energy hurts the eurozone economy.

    Oil is a major new factor this period, with a two-sided impact on EURUSD that explains why the euro's rally is capped.

  • ECB officials signal readiness to act, supporting euro ECB's Holzmann said no second-round inflation effects yet but the bank stands ready to act; Nagel urged caution but decisiveness if needed; Rabobank and ING note oil revives ECB hike risk. This keeps euro interest-rate appeal alive, underpinning EURUSD.

    ECB policy stance is a core driver of the euro's value versus the dollar, and this period brought fresh signals.

  • Eurozone inflation slows, ECB expected to hold rates Final June eurozone inflation was 2.8%, down from 3.2%, with core at 2.4%. Nordea expects the ECB to hold rates at its July meeting as a pause, not a pivot. Slower inflation reduces pressure to hike, limiting euro upside.

    This is a counterweight to the euro-positive ECB signals, showing why the euro isn't rising more.

▲3

ECB hawkishness and Middle East tensions drive euro higher

  • ECB signals more rate hikes, supporting euro ECB minutes showed inflation will stay above target until 2027, and markets now price nearly three rate hikes. Higher euro interest rates attract global capital, pushing EURUSD up.

    This is a key new driver: ECB's hawkish stance strengthens the euro.

  • Middle East tensions weaken dollar, lift euro US-Iran ceasefire broke down, with US strikes on Iran. The dollar usually weakens on such geopolitical risk as investors avoid US assets, helping EURUSD rise.

    New escalation in Middle East tensions is a fresh factor pushing the dollar down.

  • Strong German data boosts euro German industrial production and exports rose unexpectedly in May, signaling eurozone economic resilience. A stronger economy supports the euro, pushing EURUSD higher.

    New positive economic data from Germany supports the euro.

  • Fed rate hike bets ease, but volatility may rise Weak US jobs data and stable claims reduced Fed hike odds, weakening the dollar. However, rising FX volatility and hedging demand could cause sharp swings in EURUSD.

    This shows a counterweight: while Fed bets ease, volatility risk remains.

Q2 2026
▼3▲1

Euro Falls to One-Year Low as Fed Hawkishness and Oil Slump Weigh

  • Fed Hawkishness Draws Capital to USD Fed Chair Warsh's hawkish stance, with nine of 19 officials eyeing a year-end rate hike, pulled capital into the US dollar, pushing the euro to a one-year low near 1.1350.

    This is the main force driving the euro down against the dollar.

  • ECB Hikes Alone into Weak Growth The ECB raised rates by itself while the Eurozone economy remained weak, and President Lagarde downplayed inflation, widening the interest rate gap with the US and pressuring the euro.

    It explains why the euro struggled despite an ECB rate hike.

  • Oil Slump Cuts ECB Hike Expectations A sharp drop in oil prices from $115 to around $75 per barrel reduced the chances of further ECB rate hikes, adding to the euro's weakness.

    It shows how falling oil prices indirectly hurt the euro by lowering ECB hike odds.

  • US-Iran Peace Deal and Weak US Payrolls Lift Euro The US-Iran peace deal briefly pushed the euro above 1.1500, and later weak US payrolls (57k vs. 113k expected) sent it to a 1.5-week high, though analysts warn the dollar rally may be overdone.

    It highlights the main positive forces that temporarily lifted the euro.

June 2026
▼3▲1

Euro Falls to One-Year Low as Fed Hawkishness and Oil Slump Weigh

  • Fed Hawkishness Draws Capital to USD Fed Chair Warsh's hawkish stance, with nine of 19 officials eyeing a year-end rate hike, pulled capital into the US dollar, pushing the euro to a one-year low near 1.1350.

    This is the main force driving the euro down against the dollar.

  • ECB Hikes Alone into Weak Growth The ECB raised rates by itself while the Eurozone economy remained weak, and President Lagarde downplayed inflation, widening the interest rate gap with the US and pressuring the euro.

    It explains why the euro struggled despite an ECB rate hike.

  • Oil Slump Cuts ECB Hike Expectations A sharp drop in oil prices from $115 to around $75 per barrel reduced the chances of further ECB rate hikes, adding to the euro's weakness.

    It shows how falling oil prices indirectly hurt the euro by lowering ECB hike odds.

  • US-Iran Peace Deal and Weak US Payrolls Lift Euro The US-Iran peace deal briefly pushed the euro above 1.1500, and later weak US payrolls (57k vs. 113k expected) sent it to a 1.5-week high, though analysts warn the dollar rally may be overdone.

    It highlights the main positive forces that temporarily lifted the euro.

▲1▼1

Eurozone inflation cools, ECB hike bets fade; weak US jobs lift euro

  • Eurozone inflation cools, ECB hike bets fade Eurozone inflation slowed to 2.8% in June, below the 3% forecast, and German inflation also cooled. Traders cut bets on another ECB rate hike, reducing the euro's interest-rate appeal and pushing EURUSD down toward 1.1400.

    This is the main new force weakening the euro this period.

  • Weak US jobs data dents Fed hike expectations US June payrolls rose only 57,000, far below the 113,000 expected, and May's figure was revised down. This cooled bets on near-term Fed tightening, weakening the dollar and lifting the euro to a 1.5-week high above 1.1400.

    This is the main new force supporting the euro at the end of the period.

  • ECB still hawkish, but oil slump complicates ECB President Lagarde defended June's rate hike as necessary, and ING expects one more hike, supporting the euro. But lower oil prices reduce inflation pressure, and Commerzbank warns the ECB may not need to tighten much more, creating mixed signals.

    Shows the counterweight: ECB hawkishness supports the euro but may be fading.

▼3▲1

Euro hits one-year low as Fed hike bets and oil slump outweigh ECB

  • Fed rate-hike bets drive dollar to 13-month high, euro below 1.14 The Fed under Kevin Warsh is expected to raise rates as soon as September, pulling global money into the dollar. The euro fell below 1.1400 to a one-year low near 1.1350, as higher US rates make dollar deposits more attractive than euro ones.

    This is the main force pushing EURUSD down this period.

  • Oil price collapse cuts ECB hike odds, weakening euro support Easing US-Iran tensions and restored Hormuz oil flows sent Brent crude from $115 in May to about $75. Lower energy costs reduce inflation pressure, so traders slashed the chance of a second ECB rate hike from 50% to 20%, removing a key euro support.

    This new oil-driven shift in ECB expectations is a fresh negative for the euro.

  • ECB's Lagarde downplays inflation, signaling no aggressive tightening ECB President Lagarde said the inflation shock needs only a measured response and no forceful action, even as Eurozone PMIs stay weak with German services at a 43-month low. This contrast with the hawkish Fed widens the euro-dollar interest rate gap, pushing EURUSD down.

    Lagarde's stance is a new, direct driver of euro weakness this period.

  • Dollar rally may be overdone; lower oil and weak US data spark rebound On Friday the dollar fell for a second day as lower oil and weak US consumer sentiment cooled Fed hike expectations, lifting the euro 0.43% to 1.1418. Analysts warn the dollar-positive loop may burn out, and BofA still sees euro recovery later in 2026 on German fiscal stimulus.

    This is the real counterweight that could stop or reverse the euro's fall.

▼2▲1

Hawkish Fed under Warsh drives dollar to one-year high, euro to three-month low

  • Fed's hawkish turn under Warsh lifts USD, sinks EUR New Fed Chair Kevin Warsh's first meeting delivered a hawkish dot plot: nine of 19 officials now expect at least one rate hike by year-end. Higher US rates attract global capital to the dollar, pushing EURUSD down to a three-month low near 1.1416.

    This is the dominant new force this period, directly driving the euro to multi-month lows.

  • ECB hikes alone as other central banks hold The ECB raised rates and signaled more to come, but the BoE, SNB, Norges Bank and Riksbank stayed on hold. A lone hiker with weaker regional growth undermines the euro, as markets price downside risks for the euro area.

    Explains why ECB hikes are not supporting the euro, a key counterintuitive driver.

  • US-Iran peace deal briefly lifts euro Trump signed a memorandum with Iran to end the war, easing geopolitical tensions and weakening the safe-haven dollar. The euro rebounded above 1.1500, though the gain was short-lived as Fed rate expectations soon reasserted themselves.

    Shows a real counterweight to dollar strength, even if temporary.

  • Analysts warn dollar rally may be overdone ING cautioned the dollar's surge may not last, arguing the US-Iran deal removes a positive argument for the dollar and markets overestimate the chance of a Fed rate hike. This suggests EURUSD could stabilize or rebound if rate-hike bets fade.

    Provides a fair counterpoint that the dominant dollar-strength trend may reverse.

© 2026 MarketIVWhy